PDCD1 and familial pancreatic carcinoma: In fact, FDA approved drugs targeting the MAPK pathway are currently available.35 It also remains feasible, however, that the PD-1/PD-L1 axis may enhance pancreatic cancer growth by unexplored signaling pathways.